Jóse Ángel Arranz Arija

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias et al. · The Lancet · 2020 · 766 citations · Full text

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

Johann S. de Bono, Ugo De Giorgi, Daniel Nava Rodrigues et al. · Clinical Cancer Research · 2018 · 303 citations

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Advanced Ovarian Cancer, Medicine, Pharmacology +9

Assessing Apps for Patients with Genitourinary Tumors Using the Mobile Application Rating Scale (MARS): Systematic Search in App Stores and Content Analysis

Miguel Ángel Amor García, Roberto Collado‐Borrell, Vicente Escudero‐Vilaplana et al. · JMIR mhealth and uhealth · 2020 · 56 citations · Full text

KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Evan Y. Yu, Josep M. Piulats, Gwénaëlle Gravis et al. · Journal of Clinical Oncology · 2020 · 39 citations

Urology, Psa Response Rate, Genitourinary Cancer +14